UOC
ALGS icon

UBS O'Connor’s Aligos Therapeutics ALGS Stock Holding History

UBS O'Connor’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-40,096
Closed -$1.6M – 330
2024
Q4 		$1.6M Sell
40,096
-27,000
-40% -$522K 0.04% 183
2024
Q3 		$581K Buy
67,096
+27,096
+68% +$337K 0.01% 334
2024
Q2 		$350K Buy
40,000
+20,000
+100% +$352K 0.01% 385
2024
Q1 		$490K Buy
+20,000
New +$398K 0.01% 336

Other funds holding ALGS

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS O'Connor's ALGS Position: Q1 2025 in Review

UBS O'Connor sold out of Aligos Therapeutics (ALGS) in Q1 2025, closing a stake of 40,096 shares — an estimated $1.6M sold.

UBS O'Connor first reported a position in ALGS in Q1 2024 and held it in 4 quarters. The position peaked at $1.6M in Q4 2024. 35 funds tracked by Wall St. Rank hold ALGS as of Q1 2025.

  • UBS O'Connor reported no remaining Aligos Therapeutics position as of Q1 2025 after selling out during the quarter.
  • UBS O'Connor sold 40,096 Aligos Therapeutics shares in Q1 2025, an estimated $1.6M.
  • UBS O'Connor first reported a position in Aligos Therapeutics in Q1 2024 and held it in 4 quarters.
  • UBS O'Connor's Aligos Therapeutics position peaked at $1.6M in Q4 2024.
  • 35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2025.

Based on UBS O'Connor's 13F filing for Q1 2025, filed 15 May 2025.